ALK Valuation Multiples

ALK Overview

About ALK

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Founded

1923

HQ

Employees

2.7K

Website

alk.net

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $321M

EV

$8B

Valuation Multiples

Multiples.vc

Start free trial

ALK Financials

ALK reported last 12-month revenue of $1B and EBITDA of $321M.

In the same LTM period, ALK generated $692M in gross profit, $321M in EBITDA, and $197M in net income.

ALK P&L

In the most recent fiscal year, ALK reported revenue of $996M and EBITDA of $313M.

ALK expects next 12-month revenue of XXX and NTM EBITDA of XXX

ALK Stock Performance

ALK has current market cap of $8B, and enterprise value of $8B.

ALK's stock price is $35.06.

ALK Valuation Multiples

ALK trades at 7.4x EV/Revenue multiple, and 23.8x EV/EBITDA.

ALK Financial Valuation Multiples

As of April 21, 2026, ALK has market cap of $8B and EV of $8B.

Equity research analysts estimate ALK's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ALK has a P/E ratio of 39.5x.

ALK Margins & Growth Rates

ALK's revenue in the last 12 month grew by 13%.

ALK's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

ALK's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ALK's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

ALK Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

ALK M&A Activity

ALK acquired XXX companies to date.

Last acquisition by ALK was on XXXXXXXX, XXXXX. ALK acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

ALK Investment Activity

ALK invested in XXX companies to date.

ALK made its latest investment on XXXXXXXX, XXXXX. ALK invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).